182 related articles for article (PubMed ID: 16055338)
1. Optimisation study of alpha-cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes.
Groppi F; Bonardi ML; Birattari C; Menapace E; Abbas K; Holzwarth U; Alfarano A; Morzenti S; Zona C; Alfassi ZB
Appl Radiat Isot; 2005; 63(5-6):621-31. PubMed ID: 16055338
[TBL] [Abstract][Full Text] [Related]
2. Production of α-particle emitting ²¹¹At using 45 MeV α-beam.
Kim G; Chun K; Park SH; Kim B
Phys Med Biol; 2014 Jun; 59(11):2849-60. PubMed ID: 24819557
[TBL] [Abstract][Full Text] [Related]
3. Assessing the 210At impurity in the production of 211At for radiotherapy by 210Po analysis via isotope dilution alpha spectrometry.
Schultz MK; Hammond M; Cessna JT; Plascjak P; Norman B; Szajek L; Garmestani K; Zimmerman BE; Unterweger M
Appl Radiat Isot; 2006; 64(10-11):1365-9. PubMed ID: 16563782
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.
Larsen RH; Wieland BW; Zalutsky MR
Appl Radiat Isot; 1996 Feb; 47(2):135-43. PubMed ID: 8852627
[TBL] [Abstract][Full Text] [Related]
5. Preliminary production of 211At at the Texas A&M University Cyclotron Institute.
Martin TM; Bhakta V; Al-Harbi A; Hackemack M; Tabacaru G; Tribble R; Shankar S; Akabani G
Health Phys; 2014 Jul; 107(1):1-9. PubMed ID: 24849899
[TBL] [Abstract][Full Text] [Related]
6. An assessment of radionuclidic impurities of (210)Po produced via neutron irradiation of (209)Bi for use in targeted alpha-particle radiotherapy.
Schultz MK; Borgman MP; Coleman T; Bakhlanov S; Marchenkov N; Line BR
Appl Radiat Isot; 2007 Jul; 65(7):784-92. PubMed ID: 17466524
[TBL] [Abstract][Full Text] [Related]
7. Cyclotron production of 64Cu by deuteron irradiation of 64Zn.
Abbas K; Kozempel J; Bonardi M; Groppi F; Alfarano A; Holzwarth U; Simonelli F; Hofman H; Horstmann W; Menapace E; Lesetický L; Gibson N
Appl Radiat Isot; 2006 Sep; 64(9):1001-5. PubMed ID: 16500108
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of cyclotron production parameters for the 209Bi(alpha, 2n) 211At reaction related to biomedical use of 211At.
Henriksen G; Messelt S; Olsen E; Larsen RH
Appl Radiat Isot; 2001 May; 54(5):839-44. PubMed ID: 11258534
[TBL] [Abstract][Full Text] [Related]
9. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.
Moustapha ME; Ehrhardt GJ; Smith CJ; Szajek LP; Eckelman WC; Jurisson SS
Nucl Med Biol; 2006 Jan; 33(1):81-9. PubMed ID: 16459262
[TBL] [Abstract][Full Text] [Related]
10. A versatile technique for radiochemical separation of medically useful no-carrier-added (nca) radioarsenic from irradiated germanium oxide targets.
Chattopadhyay S; Pal S; Vimalnath KV; Das MK
Appl Radiat Isot; 2007 Nov; 65(11):1202-7. PubMed ID: 17656098
[TBL] [Abstract][Full Text] [Related]
11. Production study of high specific activity NCA Re-186g by proton and deuteron cyclotron irradiation.
Bonardi ML; Groppi F; Manenti S; Persico E; Gini L
Appl Radiat Isot; 2010 Sep; 68(9):1595-601. PubMed ID: 20399107
[TBL] [Abstract][Full Text] [Related]
12. Excitation functions of natGe(p,xn)71,72,73,74 As reactions up to 100 MeV with a focus on the production of 72 As for medical and 73 As for environmental studies.
Spahn I; Steyn GF; Nortier FM; Coenen HH; Qaim SM
Appl Radiat Isot; 2007 Sep; 65(9):1057-64. PubMed ID: 17574855
[TBL] [Abstract][Full Text] [Related]
13. Study of the 192Os(d,2n) reaction for production of the therapeutic radionuclide 192Ir in no-carrier added form.
Tárkányi F; Hermanne A; Takács S; Hilgers K; Kovalev SF; Ignatyuk AV; Qaim SM
Appl Radiat Isot; 2007 Nov; 65(11):1215-20. PubMed ID: 17681800
[TBL] [Abstract][Full Text] [Related]
14. An overview of copper radionuclides and production of 61Cu by proton irradiation of (nat)Zn at a medical cyclotron.
Rowshanfarzad P; Sabet M; Jalilian AR; Kamalidehghan M
Appl Radiat Isot; 2006 Dec; 64(12):1563-73. PubMed ID: 16377202
[TBL] [Abstract][Full Text] [Related]
15. Cyclotron production of (99m)Tc: experimental measurement of the (100)Mo(p,x)(99)Mo, (99m)Tc and (99g)Tc excitation functions from 8 to 18 MeV.
Gagnon K; Bénard F; Kovacs M; Ruth TJ; Schaffer P; Wilson JS; McQuarrie SA
Nucl Med Biol; 2011 Aug; 38(6):907-16. PubMed ID: 21843787
[TBL] [Abstract][Full Text] [Related]
16. Astatine-211: production and availability.
Zalutsky MR; Pruszynski M
Curr Radiopharm; 2011 Jul; 4(3):177-85. PubMed ID: 22201707
[TBL] [Abstract][Full Text] [Related]
17. Cyclotron production of Ac-225 for targeted alpha therapy.
Apostolidis C; Molinet R; McGinley J; Abbas K; Möllenbeck J; Morgenstern A
Appl Radiat Isot; 2005 Mar; 62(3):383-7. PubMed ID: 15607913
[TBL] [Abstract][Full Text] [Related]
18. Radionuclide impurities in proton-irradiated [18O]H2O for the production of 18F-: activities and distribution in the [18F]FDG synthesis process.
Bowden L; Vintró LL; Mitchell PI; O'Donnell RG; Seymour AM; Duffy GJ
Appl Radiat Isot; 2009 Feb; 67(2):248-55. PubMed ID: 19111472
[TBL] [Abstract][Full Text] [Related]
19. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.
Lindegren S; Albertsson P; Bäck T; Jensen H; Palm S; Aneheim E
Cancer Biother Radiopharm; 2020 Aug; 35(6):425-436. PubMed ID: 32077749
[TBL] [Abstract][Full Text] [Related]
20. Experimental study of the cross-sections of alpha-particle induced reactions on 209Bi.
Hermanne A; Tárkányi F; Takács S; Szücs Z; Shubin YN; Dityuk AI
Appl Radiat Isot; 2005 Jul; 63(1):1-9. PubMed ID: 15866442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
